Capricor Therapeutics Securities Fraud Investigation
Capricor Therapeutics · Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy · Ongoing Litigation
About this case
The complaint alleges that Capricor Therapeutics and certain senior executives made materially false or misleading statements concerning Deramiocel and the integrity of clinical data supporting its Biologics License Application, allegedly causing investors losses when the company’s stock price declined. The securities class action is pending in the U.S. District Court for the Southern District of California.
Case overview
- Defendant company
- Capricor Therapeutics
- Product or service
- Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy
- Case name
- Nkamga v. Capricor Therapeutics, Inc.
- Court case number
- 26-cv-04385
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Lead plaintiff application
- Lead Plaintiff Application
Participation information
Lead plaintiff application
Investors who purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026, inclusive, may seek appointment as lead plaintiff.
Provide your information through the Robbins Geller intake page by September 28, 2026.
- Type
- Lead Plaintiff
- Status
- Open
- Reported proof requirement
- Unclear
Lead Plaintiff Application
Investors in Capricor securities may ask the court to appoint them as lead plaintiff, subject to the court’s requirements.
Submit information to Bleichmar Fonti & Auld LLP to discuss rights and a potential lead-plaintiff application.
- Type
- Lead Plaintiff
- Status
- Open
- Reported proof requirement
- Unclear
Sources
- Capricor Therapeutics Securities Fraud Class Action
Barchart.com ·
- Capricor Therapeutics Securities Fraud Class Action
Barchart.com ·
- Capricor Therapeutics Securities Class Action
Barchart.com ·
- Capricor Therapeutics Securities Fraud Investigation
Barchart.com ·